Mark J. Gergen - 10 Dec 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.

Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
10 Dec 2024
Net transactions value
-$200,436
Form type
4
Filing time
11 Dec 2024, 17:17:56 UTC
Previous filing
27 Nov 2024
Next filing
03 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Options Exercise $83,430 +30,000 +4.6% $2.78 681,291 10 Dec 2024 Direct F1
transaction PSTX Common Stock Sale $283,866 -30,000 -4.4% $9.46* 651,291 10 Dec 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Options Exercise $0 -30,000 -24% $0.000000 96,372 10 Dec 2024 Common Stock 30,000 $2.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sale reported in this Form 4 were effected pusuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 21, 2024.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.44 to $9.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock option is fully vested and exerciseable.